Arecor Therapeutics plc (AIM:AREC)
London · Delayed Price · Currency is GBP · Price in GBX 63.50
-0.39 (-0.61%)
Aug 15, 2025, 4:35 PM GMT+1
Arecor Therapeutics Revenue
In the year 2024, Arecor Therapeutics had annual revenue of 5.05M GBP with 10.50% growth. Arecor Therapeutics had revenue of 3.06M in the half year ending December 31, 2024, with 78.83% growth.
Revenue
5.05M
Revenue Growth
+10.50%
P/S Ratio
4.74
Revenue / Employee
114.84K
Employees
44
Market Cap
23.98M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 5.05M | 480.00K | 10.50% |
| Dec 31, 2023 | 4.57M | 2.17M | 90.30% |
| Dec 31, 2022 | 2.40M | 1.25M | 107.51% |
| Dec 31, 2021 | 1.16M | -540.00K | -31.80% |
| Dec 31, 2020 | 1.70M | -192.99K | -10.21% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| May 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| May 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| AstraZeneca | 41.24B |
| GSK plc | 31.63B |
| Haleon | 11.02B |
| Smith & Nephew | 4.33B |
| ConvaTec Group | 1.72B |
| Hikma Pharmaceuticals | 2.35B |
| Oxford Nanopore Technologies | 183.19M |
| HUTCHMED (China) | 439.54M |
Arecor Therapeutics News
- 5 weeks ago - Skye Bioscience Partners With Arecor: Potentially Enhanced Nimacimab Dosing - Seeking Alpha
- 3 months ago - AIM Market Roundup: The Revel Collective, Tanfield, Arecor - The Armchair Trader
- 3 months ago - Full Year 2024 Arecor Therapeutics PLC Earnings Presentation (Shareholder Q&A) Transcript - GuruFocus
- 11 months ago - Half Year 2024 Arecor Therapeutics PLC Earnings Presentation Transcript - GuruFocus